drugset
drugset / Trial / NCT02790710

Brief Intervention for OCD Fears

NCT02790710 ↗

Phase 4 Withdrawn New York State Psychiatric Institute
RandomizedParallel-groupTriple-blindOther

Summary

The study will test the efficacy of propranolol or placebo, administered after reactivation of a previously acquired obsessive-compulsive disorder (OCD) fear, in reducing fear and avoidance in OCD.

Timeline

Start
2016-06
Primary completion
2023-04
Completion
2023-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Propranolol Small molecule 40 mg —

Indications

obsessive-compulsive disorder